National Vector Borne Disease Control Programme (NVBDCP)
NVBDCP is India's umbrella programme for prevention and control of six vector-borne diseases: Malaria, Dengue, Chikungunya, Japanese Encephalitis (JE), Lymphatic Filariasis (LF) and Kala-azar (Visceral Leishmaniasis). Together these diseases cause over 10 lakh clinically suspected cases annually in India and disproportionately affect the poorest rural and peri-urban populations.
NVBDCP was launched in 2003-04 by merging the National Anti-Malaria Programme (NAMP), the National Filaria Control Programme (NFCP), the Kala-azar Control Programme, and the Japanese Encephalitis Control Programme into a single integrated programme. It is one of the few programmes that combines prevention (vector control), diagnosis (rapid diagnostic kits), treatment (anti-parasitic drugs), and surveillance under one administrative umbrella at central, state and district level.
NVBDCP is centrally sponsored with 75:25 centre-state funding (90:10 for North-East). Annual outlay is approximately Rs 700 crore. The programme is implemented through District Vector Borne Disease Control Officers (DVBDCOs) supported by Multi-Purpose Health Workers (MPHWs), biologists, and field volunteers.
| Disease | Vector | Annual Burden (India) | Status |
|---|---|---|---|
| Malaria | Female Anopheles | ~2 lakh cases, <100 deaths | Elimination phase by 2030 |
| Dengue | Aedes aegypti / albopictus | ~1-3 lakh cases | Hyper-endemic urban |
| Chikungunya | Aedes aegypti / albopictus | ~50,000 cases | Outbreak-driven |
| Japanese Encephalitis | Culex tritaeniorhynchus | ~3,000 cases, AES ~10,000 | Endemic in 24 states |
| Lymphatic Filariasis | Culex quinquefasciatus | ~6.5 crore at risk | Elimination target 2027 |
| Kala-azar (VL) | Phlebotomus argentipes | <3,000 cases | Elimination target 2023-25 |
India's National Framework for Malaria Elimination (NFME) 2016-2030 aims to eliminate malaria (zero indigenous cases) by 2030. The framework classifies states into four categories based on Annual Parasite Incidence (API):
- Category 0: States with no indigenous cases (e.g., Himachal, J&K, Punjab)
- Category 1: API < 1 per 1,000 population (e.g., Tamil Nadu, Karnataka)
- Category 2: API < 1 in all districts, but some districts have local transmission
- Category 3: API ≥ 1 in any district (mostly North-East and tribal areas)
Key interventions: Long-Lasting Insecticidal Nets (LLINs) distributed free in high-burden districts, Indoor Residual Spraying (IRS) with synthetic pyrethroids in API > 1 areas, Rapid Diagnostic Tests (RDTs) for falciparum detection at sub-centre level, Artemisinin-based Combination Therapy (ACT) for P. falciparum, Chloroquine for P. vivax, and reactive case detection around every confirmed case.
There is no specific anti-viral treatment for dengue, so NVBDCP focuses on (1) early case detection, (2) clinical management to prevent deaths from severe dengue, and (3) vector control. Dengue diagnostic algorithm under NVBDCP:
- NS1 antigen ELISA — for first 5 days of fever (sensitivity > 90%)
- IgM antibody ELISA — from day 5 to day 30 of illness
- RT-PCR — early, confirmatory but expensive; available at district level
Vector control includes source reduction (every Friday is observed as Dry Day in schools and offices), anti-larval measures (temephos, Bti), and fogging with pyrethrum during outbreaks. Clinical management follows the WHO classification (Dengue without warning signs, Dengue with warning signs, Severe Dengue) with strict fluid balance protocols — over-hydration is the most common iatrogenic complication. The case fatality rate can be kept below 0.5% with proper management but exceeds 5% in untreated severe cases.
India's Kala-azar elimination target is < 1 case per 10,000 population at block level. As of 2024, only ~3,000 cases are reported annually, concentrated in Bihar (majority), Jharkhand, West Bengal and Uttar Pradesh. The strategy involves:
- Single-dose Liposomal Amphotericin B (LAmB, 10 mg/kg IV over 2 hours) — the standard first-line treatment since 2017. Free of cost through NTEP supply chain.
- Indoor Residual Spraying (IRS) with synthetic pyrethroids in all endemic villages, two rounds per year
- Active case finding through house-to-house fever surveys
- Vector control of Phlebotomus argentipes sandfly
- Post-Kala-azar Dermal Leishmaniasis (PKDL) surveillance — a human reservoir that perpetuates transmission
India signed a tripartite MoU with Bangladesh and Nepal in 2005 for cross-border Kala-azar elimination — one of the few cross-border public health collaborations in South Asia.
India carries 40% of the global Lymphatic Filariasis (LF) burden. The elimination strategy uses Mass Drug Administration (MDA) with a single annual dose of Diethylcarbamazine citrate (DEC, 6 mg/kg) plus Albendazole (400 mg) to entire eligible populations in endemic districts, repeated for 5-7 years to break transmission. The original triple-drug regimen (IDA — Ivermectin + DEC + Albendazole) was introduced in 2019 in selected districts for faster transmission interruption.
For patients with established lymphoedema or hydrocele, NVBDCP provides Morbidity Management and Disability Prevention (MMDP) services — hygiene training, compression bandages, and surgical hydrocelectomy at designated centres. Elimination target is 2027. Reference: nvbdcp.gov.in.
NVBDCP's challenge is that each of its six target diseases requires a different vector control strategy, different drug, and different surveillance approach. For UPSC CMS aspirants, this is one of the most exam-relevant programmes — questions on malaria treatment by species, dengue fluid management, kala-azar single-dose LAmB, and LF MDA appear regularly in PSM papers.